Prostate Cancer Clinical Trials Consortium Clinical Research Site: University of Washington (UWash)
Abstract
Purpose: Participate as an active and productive member of the Prostate Cancer Clinical Trial Consortium (PCCTC) throughout the funding period. Scope: This is the annual report summarizing the site activities for the University of Washington (UWash) for the funding period 01Oct2019-30Sep2020. Major Progress: In the last year, UWash was the lead/co-lead site on 10 trials and completed accrual on 5 trials. Results: UWash accrued 28 patients to PCCTC trials. Significance: The PCCTC provides a mechanism for participation in early clinical development of novel agents and rapid testing of these agents for the treatment of prostate cancer. Many of the PCCTC trials have challenging entry criteria such as a biopsy of metastatic tissue or complicated pharmacokinetics/pharmacodynamics, and collection of correlative biomarkers. The PCCTC is well positioned to conduct such trials that might not be possible outside of sites that specialize in prostate cancer translational research. Shortening drug development time with better trial design, patient selection, and validation of biomarkers will bring new agents to prostate cancer patients faster, optimize treatment for the individual patient, and avoid treating others with ineffective therapies.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2020
- Accession Number
- AD1125840
Entities
People
- Celestia Higano
- Evan Yu
- Heather Cheng
Organizations
- University of Washington